September 9, 2025
Mrs. Cammack (for herself, Ms. Kamlager-Dove, Mrs. Kim, Ms. Pettersen, Mrs. Hinson, Ms. Adams, Mrs. Cherfilus-McCormick, and Mr. Landsman) submitted the following resolution; which was referred to the Committee on Energy and Commerce
Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.
Whereas antiphospholipid syndrome (APS) is a condition in which the immune system of an individual mistakenly produces antibodies that increase the risk of blood clots;
Whereas APS can increase the risk of miscarriages, stillbirths, and pregnancy complications;
Whereas professional medical associations and guideline-setting bodies do not recommend testing for APS as a standard part of prenatal screening;
Whereas professional medical associations and guideline-setting bodies recommend testing for APS only if a woman has an unexplained fetal loss after 10 weeks or 3 or more unexplained embryonic losses (miscarriages);
Whereas APS is responsible for about 15 percent of recurrent pregnancy losses;
Whereas the total number of miscarriages caused by APS is unknown because it is not tested as part of normal prenatal screening;
Whereas APS can be detected by a blood test and treated by blood thinners; and
Whereas testing for APS during normal prenatal screening can save babies and reduce grief for women and families: Now, therefore, be it
That the House of Representatives—
(1)
supports testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening; and
(2)
calls upon professional medical associations and guideline-setting bodies to update their recommendations to include testing for APS as a standard part of prenatal screening.